Allorion Therapeutics
PrivateLast Round
Series B
Mar 9, 2023
Total Funding Raised
$105M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Allorion Therapeutics operates in Healthcare & Life Sciences and is based in Natick, Massachusetts. Its latest recorded funding round was a Series B round in March 2023.
Allorion Therapeutics is a biopharmaceutical company that develops innovative small-molecule drugs aimed at treating cancer and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Allorion Therapeutics Comparables
Compare Allorion Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Avenzo Therapeutics | 84% | |
| NiKang Therapeutics | 84% | |
| AnHorn Medicines | 83% |
For institutional investors. Book with your work email.
Allorion Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Mar 9, 2023 | ||||
| Series A | Nov 24, 2021 | ||||
| Angel | Jul 1, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Allorion Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Longriver Investment Partners | Series B |
| IDG Capital | Series A |
| Firstred Capital | Series A |
| TF Capital | Angel, Series A, Series B |
| 渶策资本 | Series B |
| Elikonventure.com | Series A, Series B |
| LongRiver Investments | Series B |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 50% MoM.
- Jul 27, 2026
Monthly visitors grew 137% MoM, reaching 2.1K.
For institutional investors. Book with your work email.
Allorion Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Allorion Therapeutics's valuation, stock price, and market status.
Is Allorion Therapeutics a public or private company?
Allorion Therapeutics is a private company.
What is the current stock price of Allorion Therapeutics?
Allorion Therapeutics is a private company, so its shares have no public market price. Caplight tracks Allorion Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Allorion Therapeutics worth (valuation)?
Valuation information for Allorion Therapeutics is not publicly available.
Can I buy Allorion Therapeutics stock?
Allorion Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Allorion Therapeutics's last funding round?
Allorion Therapeutics's most recent funding round was Series B on March 9, 2023.
Who are the main investors in Allorion Therapeutics?
Key investors in Allorion Therapeutics include 渶策资本, Qiming Venture Partners.
Will Allorion Therapeutics IPO soon?
No public IPO plans have been announced for Allorion Therapeutics.
How can I track Allorion Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Allorion Therapeutics's shares on secondary markets.